Elicio Therapeutics, Inc. (ELTX)
1.68
-0.07
(-4.00%)
USD |
NASDAQ |
Oct 30, 16:00
1.695
+0.02
(+0.89%)
After-Hours: 20:00
Elicio Therapeutics Enterprise Value : 27.46M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 27.46M |
| October 29, 2026 | 29.00M |
| October 28, 2026 | 31.19M |
| October 27, 2026 | 30.75M |
| October 26, 2026 | 27.90M |
| October 23, 2026 | 32.28M |
| October 22, 2026 | 33.16M |
| October 21, 2026 | 27.24M |
| October 20, 2026 | 25.05M |
| October 19, 2026 | 24.62M |
| October 16, 2026 | 24.83M |
| October 15, 2026 | 29.65M |
| October 14, 2026 | 29.87M |
| October 13, 2026 | 29.43M |
| October 12, 2026 | 31.84M |
| October 09, 2026 | 32.06M |
| October 08, 2026 | 30.31M |
| October 07, 2026 | 31.19M |
| October 06, 2026 | 31.84M |
| October 05, 2026 | 32.72M |
| October 02, 2026 | 32.72M |
| October 01, 2026 | 32.72M |
| September 30, 2026 | 30.53M |
| September 29, 2026 | 30.97M |
| September 28, 2026 | 31.19M |
| Date | Value |
|---|---|
| September 25, 2026 | 30.97M |
| September 24, 2026 | 31.84M |
| September 23, 2026 | 31.62M |
| September 22, 2026 | 31.62M |
| September 21, 2026 | 32.50M |
| September 18, 2026 | 32.06M |
| September 17, 2026 | 31.51M |
| September 16, 2026 | 29.43M |
| September 15, 2026 | 34.25M |
| September 14, 2026 | 34.47M |
| September 11, 2026 | 35.57M |
| September 10, 2026 | 36.88M |
| September 09, 2026 | 38.41M |
| September 08, 2026 | 42.14M |
| September 04, 2026 | 43.45M |
| September 03, 2026 | 45.42M |
| September 02, 2026 | 46.52M |
| September 01, 2026 | 46.74M |
| August 31, 2026 | 49.80M |
| August 28, 2026 | 52.87M |
| August 27, 2026 | 56.37M |
| August 26, 2026 | 55.93M |
| August 25, 2026 | 56.59M |
| August 24, 2026 | 55.93M |
| August 21, 2026 | 57.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lineage Cell Therapeutics, Inc. | 203.26M |
| Armata Pharmaceuticals, Inc. | 411.84M |
| Voyager Therapeutics, Inc. | 21.62M |
| Black Diamond Therapeutics, Inc. | 8.718M |
| Invivyd, Inc. | 19.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.217M |
| Total Expenses (Quarterly) | 8.217M |
| EPS Diluted (Quarterly) | -0.427 |
| Earnings Yield | -125.8% |
| Normalized Earnings Yield | -127.38 |